News Roche’s Tecentriq combo extends life in advanced NSCLC Roche has announced that its phase 3 IMpower130 study met its co-primary endpoints of overall survival and progression-free survival in non-small cell lung cancer (NSCLC).
Views & Analysis ASCO 2018 Preview – what to expect from this year’s conferen... pharmaphorum will be presenting live online coverage of this year’s ASCO 2018 conference, the biggest event of the year for cancer medicine.
News Evotec and Celgene unite to drive forward oncology R&D Evotec and Celgene have joined forces in a long-term strategic drug discovery and development partnership, to identify new therapeutics in oncology.
Events Partner Content Rational Combinations 360 Addressing key aspects across all facets of combination
News Kite expands manufacturing capacity for CAR-T therapies Less than a year after it was acquired by Gilead in a $11.9 billion deal,
News Roche cancer guru quits to lead 'off-the-shelf' T-cell R&D a... San Francisco biotech developing therapy for post-transplant blood disorder
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.